[Objectives]To investigate the clinical effect of Yinhuang Qingfei capsules in the treatment of asymptomatic and mild/common severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection.[Methods]A total of 362...[Objectives]To investigate the clinical effect of Yinhuang Qingfei capsules in the treatment of asymptomatic and mild/common severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection.[Methods]A total of 362 patients with SARS-CoV-2 infection were divided into the treatment group with 242 patients and control group with 120 patients according to their treatment regimen.The patients in the control group were given standard treatment regimen and those in the treatment group were given Yinhuang Qingfei capsules in addition to the treatment in the control group.The two groups were observed in terms of average length of hospital stay,mean time for nucleic acid clearance,TCM syndrome score,and progression to severe/critical illness,and clinical outcome was compared between the two groups.[Results]There was a significant difference in the overall response rate between the treatment group and the control group[97.52%(236/242)vs 95.00%(114/120),P<0.05].Compared with the control group,the treatment group had significantly shorter length of hospital stay and time for nucleic acid clearance(P<0.05).After 7 days of treatment,both groups had a significant change in TCM syndrome score,and there was a significant difference in TCM syndrome score between the two groups(P<0.05);after 15 days of treatment,both groups had a TCM syndrome score of 0.Progression to severe/critical illness was not observed in either group.[Conclusions]Compared with the standard treatment regimen alone,standard treatment regimen combined with Yinhuang Qingfei capsules can effectively shorten the length of hospital stay and time for nucleic acid clearance and improve TCM symptoms in patients with asymptomatic and mild/common SARS-CoV-2 infection.展开更多
This work is aimed to study the therapeutics and pharmacology of the treatment of severe acute respiratory infection caused by coronavirus disease-19 (COVID-19) with traditional Chinese medicine (TCM) “Qingfei Paidu ...This work is aimed to study the therapeutics and pharmacology of the treatment of severe acute respiratory infection caused by coronavirus disease-19 (COVID-19) with traditional Chinese medicine (TCM) “Qingfei Paidu Decoction”. We analyze the “Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia” (Version I to Version VII) made by China, “Clinical management of severe acute respiratory infection when novel coronavirus <span style="font-family:Verdana;">(2019-nCoV) infection is suspected—Interim guidance” made by World Healt</span><span style="font-family:Verdana;">h Organization (WHO), “Therapeutic Guidelines: Respiratory” published by Australia, and the origin of classical prescription of Qingfei Paidu Decoction: “Shanghan Lun (Treatise on Febrile Diseases)” and “Jinkui Yaolue (Synopsis of Golden Chamber)”. We search the dictionary of traditional Chinese medicine (Version II) manually. We search literatures from 2001 to 2020 on Wiley online library. We conduct a comparative study on the therapeutic options and indications among Qingfei Paidu Decoction, COVID-19 and chronic obstructive pulmonary disease (COPD). And we carry out pharmacological inquiry of Qingfei Paidu Decoction. The therapeutic options and indications of Qingfei Paidu Decoction in China, COVID-19 and COPD are considered to be basically consistent. Qingfei Paidu Decoction has a definite therapeutic effect on the symptoms, basic diseases and complications for COVID-19 and COPD. Qingfei Paidu Decoction is a possible choice of </span><span style="font-family:Verdana;">phytotherapy </span><span style="font-family:Verdana;">for severe acute respiratory infection caused by COVID-19.</span>展开更多
Objective:Qingfei oral liquid(QF),an experimental Chinese medicine prescription developed from the ancient priscription of traditional Chinese medicines Ma Xin Shi Gan decoction and Tingli Dazao Xie Fei decoction,has ...Objective:Qingfei oral liquid(QF),an experimental Chinese medicine prescription developed from the ancient priscription of traditional Chinese medicines Ma Xin Shi Gan decoction and Tingli Dazao Xie Fei decoction,has been effectively used since decades to treat patients with viral pneumonia and asthma.In our previous study,we had demonstrated that QF can significantly reduce airway hyperresponsiveness,hyperemia,lung tissue edema,inflammatory lung tissue infiltration in mice,airway mucus secretion,and peripheral airway collagen hyperplasia;however,its mechanism of action is unknown.Methods:Fifty 6–8-week-old male BALB/c mice were equally and randomly divided into five groups:the control,ovalbumin(OVA),OVA+respiratory syncytial virus(RSV),QF,and dexamethasone(Dxms)groups.The QF group was administered QF at 1.17 g·kg−1·d−1,the Dxms group received dexamethasone injections at 0.2 mg·kg−1·d−1,and the remaining groups were administered PBS.Inflammation in the lung tissue was assessed by hematoxylin and eosin(HE),periodic acid–Schiff(PAS),and Van Gieson staining.ELISA was used to evaluate the IL-13,IL-25,and IL-33 in the mice.Western blotting was used to examine changes in the proteins levels of transient receptor potential vanilloid-1(TRPV1)and mucin 5AC(MUC5AC)in the lung tissues of mice.Results:Histopathological evaluation revealed that the OVA and OVA+RSV groups exhibited lung tissue edema and inflammatory lung tissue infiltration in the HE staining and airway secretions in the PAS staining;collagen hyperplasia around the airway was increased in these two groups compared with the control group.The QF group exhibited significantly reduced lung tissue edema,inflammatory lung tissue infiltration,airway secretions,and collagen hyperplasia around the airway compared with the OVA+RSV group.We analyzed the serum levels of IL-13,IL-25,and IL-33 in the mice and found that these levels were higher in the OVA and OVA+RSV groups than in the control group(P<0.05 in the OVA group,P<0.01 in the OVA+RSV group).The QF group exhibited significantly decreased serum levels of IL-13,IL-25,and IL-33 compared with the OVA+RSV group(all P<0.05).The Dxms group also exhibited significant decreases in the serum levels of IL-13 and IL-33(all P<0.05)but no significant decrease in the serum levels of IL-25 compared with the RSV+OVA group.Finally,we examined the protein levels of TRPV1 and MUC5AC in the lung tissues of mice using Western blotting.After identifying RSV infection in the mice with asthma,the protein levels of TRPV1 and MUC5AC in the lung tissues of mice were significantly higher than those in the control group(P<0.05,P<0.01).We found that compared with RSV+OVA,QF can significantly downregulate the protein level of TRPV1;further,the protein level of MUC5AC was also significantly reduced(all P<0.001).Conclusion:QF can inhibit RSV replication and reduce airway inflammation and mucus hypersecretion injury caused by RSV infection and asthma,and its mechanism of action may be associated with the downregulation of TRPV1 expression and a decrease in airway mucus hypersecretion injury.展开更多
Objective:To explore the possible mechanism of Qingfei Paibu Decoction in the treatment of COVID-19 from the perspective of cytokine storm by network pharmacology.Methods: The TCMSP and SymMap databases were used to s...Objective:To explore the possible mechanism of Qingfei Paibu Decoction in the treatment of COVID-19 from the perspective of cytokine storm by network pharmacology.Methods: The TCMSP and SymMap databases were used to screen out the active components and targets of Qingfei Paibu Decoction;The GeneCards database was used to screen the predicted targets of COVID-19;Two targets were mapped;The STRING database and Cytoscape3.7.2 software were used to construct the network diagram of active drag-ingredient-target and screen out the core components and targets;The GO enrichment analysis and KEGG pathway enrichment analysis were carried out by OmicShare cloud platform and David respectively.Results:A total of 52 potential targets of Qingfei Paibu Decoction for the treatment of COVID-19 were obtained, among which 17 were core targets related to inflammation, mainly including cytokines such as IL, IFN, TNF and chemokines. And 26 core components were obtained, including quercetin, luteolin, kaempferol, naringenin, and baicalein;The GO enrichment results showed 224 biological processes, 15 molecular functions and 33 cell components related to inflammation;There were 5 inflammatory signaling pathways in KEGG enrichment results, including TNF signaling pathway, Nod-like receptor signaling pathway, Toll-like receptor signaling pathway, MAPK signaling pathway and cytokine receptor interaction. Conclusion: Qingfei Paibu Decoction can inhibit cytokine storms by acting on multiple targets and pathways with multiple components and thus treat COVID-19.展开更多
The coronavirus disease 2019(COVID-19)was a newly discovered infectious respiratory disease and characterized by wide prevalence,high incidence rate and fast progress and dangerous,which belonged to the category of&qu...The coronavirus disease 2019(COVID-19)was a newly discovered infectious respiratory disease and characterized by wide prevalence,high incidence rate and fast progress and dangerous,which belonged to the category of"cold-wet plague"in TCM.The onset of COVID-19 was caused by pestilence,which mingled with seasonal cold-dampness and invaded the human body when external defensive qi was weak and then leaded to the accumulation of Yang qi.Different from exogenous pathogenic factors transmitted from the external to the internal or followed the transmission law of Wei,Qi,Ying and Xue,the nature of pestilence belonged to the category of pathogenic fire,spreading as soon as possible,from the external to the internal and from the upper and lower part of triple energizer,even to every part.At the very beginning,the pestilence attacked from the Taiyang meridian into the Yangming meridian quickly,or straight into the three Yang meridian,which was called"triple-yang combination of diseases".Manifestations of fever,aversion to cold and pain of body were conformed to the exterior syndrome of Taiyang,as well as manifestations of fullness and discomfort in chest,vomiting and spitting and diarrhea were conformed to the syndrome of half-interior-half-exterior;And symptoms manifested as high fever,faint,and abdominal fullness and constipation were conformed to the syndrome of Yangming;But sometimes,there was cold-dampness surrounding the exterior at the beginning along with intense interior pathogenic fire.Or at the beginning,the exterior factors invaded into three Yin meridians quickly while have not been eliminated,which may lead to the syndrome of inner blocking causing collapse or Jue exhaustion.The most typical syndrome of COVID-19 was triple-yang combination of diseases,which was often seen in mild,moderate and part of severe cases.Hence"Qingfei Paidu Decoction"was prescribed especially for this kind of syndrome.Its accurate efficacy has been proved by that mild cases converting to severe cases in the mobile cabin hospital have been effectively restrained and thus the progression of the disease has blocked.Composition analysis showed that Mahuang decoction with Maxing Shigan decoction was to relieve exterior Taiyang syndrome,Xiaochaihu decoction was for harmonizing half-superficies and half-interior Shaoyang syndrome,and large dose of gypsum was used to clear interior heat of the Yangming meridian,and Shegan Mahuang decoction and Xiaoqinglong plus gypsum decoction was for lowering the adverse qi and resolving fluid,and Wuling San was for warming the triple energizer and transforming qi and draining water."Qingfei Paidu Decoction"was an syncretic innovation of classical prescriptions from Treatise on Febrile Diseases,which was not made up of herbs but multiple concordant prescriptions helping to get twice the result with half the effort,so that the"cold-wet plague"can be quickly discharged.展开更多
Objective:To investigate the mechanism of regulation of airway neurogenic inflammation by Qiaoqin Qingfei agent in rats with cough variant asthma(CVA).Methods:48 SD rats were randomly divided into blank group,model gr...Objective:To investigate the mechanism of regulation of airway neurogenic inflammation by Qiaoqin Qingfei agent in rats with cough variant asthma(CVA).Methods:48 SD rats were randomly divided into blank group,model group,montelukast sodium group(1.05 mg/kg)and high,medium and low dose groups(26,13,6.5 g/kg),with 8 rats in each group.The rat CVA model was established by the method of ovalbumin(OVA)combined with aluminum hydroxide(Al(OH)3)sensitization and repeated stimulation.From the second day of sensitization,the rat CVA model was given by gavage for 28 days.The pathological changes of lung tissue were observed under microscope by HE staining.The content changes of nerve growth factor(NGF)and substance P(SP)in alveolar lavage fluid(BALF)were determined by double-antibody sandwich ABC-ELISA,and the protein expression levels of NGF and SP in lung tissue were detected by immunohistochemistry.Results:Pathological findings showed significant inflammatory manifestations in the model group,and the inflammatory infiltration in the high-dose,medium-dose and low-dose groups of Qiaoqin Qingfei agent and montelukast sodium groups were alleviated to varying degrees.Compared with blank group,the protein expression levels of NGF and SP in lung tissue of model group were significantly increased(P<0.01).Compared with model group,the protein expression levels of NGF and SP in lung tissue and the contents of NGF and SP in alveolar lavage fluid in high-dose,medium-dose and low-dose groups and montelukast sodium group were significantly decreased(P<0.05).Conclusion:Qiaoqin Qingfei agent may reduce airway inflammation and relieve cough variant asthma by regulating the protein expression levels of NGF and SP in airway neurogenic inflammation.展开更多
Objective： To observe the effect of traditional Chinese medicine （TCM） Qingfei powder on the radiotherapy-related pneumonia in patient with non-small-cell lung cancer （NSCLC） and explore its underlying me...Objective： To observe the effect of traditional Chinese medicine （TCM） Qingfei powder on the radiotherapy-related pneumonia in patient with non-small-cell lung cancer （NSCLC） and explore its underlying mechanism. Methods： 120 NSCLC patients with the diagnosis of both radiotherapy-related pneumonia and deficiency of Qi and Yin were randomly divided into the treatment group and the model group. The patients in treatment group were given Qingfei power plus regular treatment and those in the model group were given the regular treatment. The period of observation is 30 days. Results： The combination of effective and markedly effective ratio in patients treated with Qingfei power was much higher than that in patients with regular treatment （70% vs 51.7%, P=0.04）. Conclusion： Qingfei power could nourish Qi and Yin as well as clear away lung-heat and dispel phlegm, leading to the relief of clinical symptom in NSCLC patients with radiotherapy-related pneumonia. It demonstrates that the deficiency of both Qi and Yin maybe the main Zheng pattern of patients with radiotherapy-related pneumonia.展开更多
Objective: To explore the effects of Qingfei Xiaoyan pill combined with ceftriaxone and azithromycin on immune index, oxidative stress and inflammatory index in senile CAP patients. Methods: A total of 130 patients wi...Objective: To explore the effects of Qingfei Xiaoyan pill combined with ceftriaxone and azithromycin on immune index, oxidative stress and inflammatory index in senile CAP patients. Methods: A total of 130 patients with CAP admitted to Yulin first hospital from October 2016 to December 2017 were randomly divided into control group (n = 65) and observation group (n = 65), the control group was treated with ceftriaxone combined with azithromycin, while the observation group was treated with Qingfei Xiaoyan Pill on the basis of the control group, the changes of cellular humoral immune function, oxidative stress index and inflammatory factors were compared between the two groups before and after treatment. Results: After treatment, the levels of CD4+ and CD4+/CD8+ in both groups were significantly higher than before treatment, while the level of CD8+ was significantly lower than before treatment, the levels of CD4+ and CD4+/CD8+ in the observation group were significantly higher than those in the control group, while the level of CD8+ was significantly lower than those in the control group;the levels of IgA and IgM in the observation group were significantly higher than those in the control group;the levels of MDA and SOD in the observation group were significantly lower than those in the control group, and the level of MDA in the observation group was significantly lower than that in the control group, the levels of SOD in the observation group were significantly higher than those in the control group;the levels of PCT and CRP in the two groups were significantly lower than those before treatment , and the levels of PCT and CRP in the observation group were significantly lower than those in the control group. Conclusions:Qingfei Xiaoyan pill combined with ceftriaxone and azithromycin can effectively enhance the immune function of elderly patients with CAP, enhance the body's antioxidant effect and reduce its inflammatory reaction, which is of clinical significance.展开更多
[Objectives]This study was conducted to explore the curative effect of Qingfei Ditan decoction combined with targeted drug penetration therapy of traditional Chinese medicine on severe mycoplasma pneumonia in children...[Objectives]This study was conducted to explore the curative effect of Qingfei Ditan decoction combined with targeted drug penetration therapy of traditional Chinese medicine on severe mycoplasma pneumonia in children.[Methods]Based on the retrospective study method,children with severe mycoplasma pneumonia admitted to the Children s Hospital of Soochow University from April 2023 to October 2023 were selected,and divided into a treatment group including 56 cases and a control group including 145 cases.The curative effect and adverse reactions of the two groups were compared.[Results]The total effective rate of the treatment group was higher than that of the control group,and the disappearance time of cough and lung rales was shorter than that of the control group,and the incidence of adverse reactions was lower,showing statistical significance(P<0.05).However,defervescence time and bronchoscope flushing rate showed no significant difference(P>0.05).[Conclusions]Qingfei Ditan Decoction combined with targeted drug penetration therapy of traditional Chinese medicine has a significant effect on severe mycoplasma pneumonia in children,and can reduce the side effects of drugs.It is a safe and efficient combination treatment scheme of traditional Chinese medicine.展开更多
OBJECTIVE:To explore how Qingfei Zhisou oral liquid(清肺止嗽口服液,QFZS)adjusts body temperature bias and the interaction of inflammatory factors levels and metabolomic differences.METHODS:Dry yeast was subcutaneously...OBJECTIVE:To explore how Qingfei Zhisou oral liquid(清肺止嗽口服液,QFZS)adjusts body temperature bias and the interaction of inflammatory factors levels and metabolomic differences.METHODS:Dry yeast was subcutaneously injected at 10 mL/kg to establish the pyrexia model.We randomly divided 60 Sprague-Dawley rats into five groups:control,model,positive,low dose of QFZS and high dose of QFZS.Inflammatory proteins were evaluated by Western blotting and immunohistochemistry.For the examination of the endogenous metabolites,enzyme linked immunosorbent assay and ultra-high-performance liquid chromatography high-resolution mass spectrometry were employed.RESULTS:QFZS significantly reduced rats'body temperature within 6 h after dry yeast injection and reduced the secretion of the arginine vasopressin,cyclic adenosine monophosphate,prostaglandin E-2,tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),and interleukin-1βin serum.Meanwhile,we identified 41 metabolites between the model and QFZS groups,including arachidonic acid and lysophospholipids.QFZS restored normal arachidonic acid levels.Based on the differential metabolite enrichment analysis,QFZS's antiinflammatory and anti-pyrexia effects might be related to the inflammatory pathway regulated by transient receptor potential.Additionally,QFZS treatment reduced transient receptor potential melastatin 2 ion channel expression and affected TNF-α,heat shock protein 70,and cyclooxygenase-2 expression in the hypothalamus.CONCLUSION:QFZS exerts its regulatory effects on fever by regulating the metabolism of lysophospholipids and arachidonic acid and the regulation of inflammation via transient receptor potential ion channels channels.展开更多
Objective: Qingfei Tongluo Plaster(QFP), an improved Chinese medicine hospital preparation, is an attractive treatment option due to its well clinical efficacy, convenience, economy, and patient compliance in the trea...Objective: Qingfei Tongluo Plaster(QFP), an improved Chinese medicine hospital preparation, is an attractive treatment option due to its well clinical efficacy, convenience, economy, and patient compliance in the treatment of respiratory syncytial virus(RSV) pneumonia. The aim of this study was to investigate the efficacy mechanism of QFP on RSV rats from the perspective of alleviating lung inflammation and further explore the changes of serum metabolites and metabolic pathways in RSV rats under the influence of QFP.Methods: This study used network pharmacological methods and molecular docking combined with molecular biology and metabolomics from multi-dimensional perspectives to screen and verify the therapeutic targets. Open online databases were used to speculate the gene targets of efficient ingredients and diseases. Then, we used the String database to examine the fundamental interaction of common targets of drugs and diseases. An online enrichment analysis was performed to predict the functional pathways. Molecular docking was applied to discover the binding modes between essential ingredients and crucial gene targets. Finally, we demonstrated the anti-inflammatory ability of QFP in the RSV-evoked pneumonia rat model and explained the mechanism in combination with the metabolomics results.Results: There were 19 critical targets defined as the core targets: tumor necrosis factor(TNF), inducible nitric oxide synthase 2(NOS2), mitogen-activated protein kinase 14(MAPK14), g1/S-specific cyclin-D1(CCND1), signal transducer and activator of transcription 1-alpha/beta(STAT1), proto-oncogene tyrosine-protein kinase Src(SRC), cellular tumor antigen p53(TP53), interleukin-6(IL6), hypoxiainducible factor 1-alpha(HIF1A), RAC-alpha serine/threonine-protein kinase(AKT1), signal transducer and activator of transcription 3(STAT3), heat shock protein HSP 90-alpha(HSP90AA1), tyrosine-protein kinase JAK2(JAK2), cyclin-dependent kinase inhibitor 1(CDKN1A), mitogen-activated protein kinase 3(MAPK3), epidermal growth factor receptor(EGFR), myc proto-oncogene protein(MYC), protein c-Fos(FOS) and transcription factor p65(RELA). QFP treated RSV pneumonia mainly through the phosphatidylinositol 3-kinase(PI3K)/RAC AKT pathway, HIF-1 pathway, IL-17 pathway, TNF pathway, and MAPK pathway. Animal experiments proved that QFP could effectively ameliorate RSV-induced pulmonary inflammation. A total of 28 metabolites underwent significant changes in the QFP treatment, and there are four metabolic pathways consistent with the KEGG pathway analyzed by network pharmacology,suggesting that they may be critical processes related to treatment.Conclusion: These results provide essential perspicacity into the mechanisms of action of QFP as a promising anti-RSV drug.展开更多
Background Chronic obstructive pulmonary disease(COPD),a common respiratory disease,can be effectively treated by traditional Chinese medicine(TCM).Qingfei Huatan,a TCM formula,has been reported to effectively allevia...Background Chronic obstructive pulmonary disease(COPD),a common respiratory disease,can be effectively treated by traditional Chinese medicine(TCM).Qingfei Huatan,a TCM formula,has been reported to effectively alleviate the clinical symptoms of COPD patients.However,there is a lack of multi-centre,randomised,double-blind,controlled clinical trials documenting the clinical efficacy and safety of this formula in the treatment of acute exacerbation of COPD(AECOPD).Objective This study evaluated the efficacy and safety of Qingfei Huatan formula in the treatment of AECOPD,thereby providing high-quality clinical evidence.Design,setting,participants and interventions A total of 276 patients with AECOPD were included in this multi-centre,randomised,double-blind,placebo-controlled trial and were randomised into treatment and control groups at a ratio of 1:1.Patients in the treatment and control groups took Qingfei Huatan granules or simulated Qingfei Huatan granules twice a day,for 14 days,in addition to Western medicine treatment.All patients were followed up for 3 months.Main outcome measures The primary outcome was time taken to symptom stabilisation.The secondary outcomes included duration of antibiotic use,clinical symptom and sign score,TCM syndrome score,dyspnoea score,and quality of life(QOL)score.Meanwhile,the safety of the formula was assessed through routine urine and stool tests,electrocardiograms,liver and kidney function tests,and the observation of adverse events throughout the trial.Results The time taken for effective stabilisation(P<0.05)and obvious stabilisation(P<0.01),and the duration of antibiotic use(P<0.05)were significantly shorter in the treatment group than in the control group.On days 6,9,12 and 14 of treatment,clinical symptom and sign score decreased in both groups,particularly in the treatment group(P<0.01).On days 9,12 and 14 of treatment,the TCM syndrome scores of both groups were reduced(P<0.01),with more significant reductions in the treatment group.At 3 months after the end of treatment,the treatment group continued to have lower clinical symptom and sign score and TCM syndrome score than the control group(P<0.01).On days 6,9,12 and 14 of treatment,dyspnoea and QOL scores were markedly reduced in the two groups(P<0.05 and P<0.01,respectively),especially in the treatment group.At 3 months after the end of treatment,dyspnoea and QOL scores were lower in the treatment group than those in the control group(P<0.01).No serious adverse events were observed in either group.Conclusion The Qingfei Huatan formula can effectively shorten the duration of AECOPD and antibiotic use,significantly relieve clinical symptoms,and increase QOL for AECOPD patients,with a favourable safety profile.These results suggest that this formula can be used as a complementary treatment for AECOPD patients.展开更多
目的探究凉血清肺汤联合硝黄搽剂湿敷治疗面部脂溢性皮炎肺胃热盛证的临床效果。方法回顾性选取2022年1月—2023年1月期间收治的面部脂溢性皮炎肺胃热盛证患者102例,根据随机数字表法分为研究组(51例),常规组(51例)。常规组进行硝黄搽...目的探究凉血清肺汤联合硝黄搽剂湿敷治疗面部脂溢性皮炎肺胃热盛证的临床效果。方法回顾性选取2022年1月—2023年1月期间收治的面部脂溢性皮炎肺胃热盛证患者102例,根据随机数字表法分为研究组(51例),常规组(51例)。常规组进行硝黄搽剂湿敷治疗,研究组采用凉血清肺汤联合硝黄搽剂湿敷治疗。比较治疗结束后患者临床疗效,比较治疗结束后患者湿疹面积及严重程度指数(eczema area severity index,EASI)、整体评分(investigator′s global assessment,IGA)、基质金属蛋白酶-3(matrix metalloproteinase-3,MMP-3)、白细胞介素-1β(interleukin-1β,IL-1β)水平,并比较治疗期间的不良反应情况。结果治疗后,两组患者中医症状评分较治疗前均降低(P<0.05),且研究组低于常规组(P<0.05),研究组、常规组治疗总有效率分别为94.12%(48/51)、72.55%(37/51),研究组较常规组高(P<0.05),治疗后两组IGA、EASI评分降低,研究组较常规组低(P<0.05),两组面部脂溢性皮炎肺胃热盛证患者治疗后MMP-3、IL-1β水平降低,研究组MMP-3、IL-1β水平较常规组低(P<0.05),两组患者不良反应率比较,差异均无统计学意义(P>0.05)。结论凉血清肺汤联合硝黄搽剂湿敷能够提高面部脂溢性皮炎肺胃热盛证患者的临床疗效,缓解症状,降低IGA、EASI评分,改善血清炎症水平,安全性较高。展开更多
Objective： To explore the effect and mechanism of Qingfei Mixture （清肺合剂）, a Chinese medicine, in treating mycoplasma pneumonia （MP） in MP patients and rat model. Methods： A total of 46 MP children with phleg...Objective： To explore the effect and mechanism of Qingfei Mixture （清肺合剂）, a Chinese medicine, in treating mycoplasma pneumonia （MP） in MP patients and rat model. Methods： A total of 46 MP children with phlegm heat obstructing Fei （Lung） syndrome were randomly assigned to two groups by the method of random number table, with 23 children in each group. The control group was treated with intravenous infusion of azithromycin; the treatment group received intravenous infusion of azithromycin and oral administration of Qingfei Mixture. The treatment course was 7 days. Major symptoms and minor symptoms were observed and scored before and after treatments. A rat model of MP was also established. A total of 120 wistar rats were randomly divided into 5 groups： a normal group, infection group, Qingfei Mixture treatment group, azithromycin treatment group, and Qingfei Mixture ＋ azithromycin treatment group. Each group contained 24 rats, from which every 6 were euthanatized 1, 3, 7 and 14 days after infection. MP DNA in pulmonary tissue homogenates was detected using real-time fluorescence quantitative polymerase chain reaction. Pathology was assessed after hematoxylin （HE） staining and lung tissue pathology scores were determined in pulmonary tissue. Transmission electron microscopic detection and electronic image analysis were performed on lung tissue 3 days after infection. Intedeukin （IL）-17 was detected in serum using enzymelinked immunosorbent assay （ELISA） 7 days after infection. Results： In the clinical study, both control and the treatment group showed improved results on removing symptoms of phlegm heat syndrome compared to the control group （P〈0.05）. In animal experiments, On the 7th day after MP infection, as detected by electron microscopy, the pulmonary capillary basement membranes of the azithromycin ＋ Qingfei Mixture treatment group were much thinner than those of the azithromycin or Qingfei mixture treatment groups （P〈0.05）. The level of serum IL-17 in the azithromycin ＋ Qingfei Mixture treatment group was lower than that in the azithromycin or Qingfei Mixture groups （P〈0.01）. Conclusion： Both Qingfei Mixture and azithromycin have therapeutic effects on mycoplasma pneumoniae pneumonia, but the combination of both agents had the greatest effect.展开更多
Respiratory syncytial virus(RSV) is a leading cause of acute lower respiratory tract infections. Qingfei oral liquid(QFOL), a traditional Chinese medicine, is widely used in clinical treatment for RSV-induced pneumoni...Respiratory syncytial virus(RSV) is a leading cause of acute lower respiratory tract infections. Qingfei oral liquid(QFOL), a traditional Chinese medicine, is widely used in clinical treatment for RSV-induced pneumonia. The present study was designed to reveal the potential targets and mechanism of action for QFOL by exploring its influence on the host cellular network following RSV infection. We investigated the serum proteomic changes and potential biomarkers in an RSV-infected mouse pneumonia model treated with QFOL. Eighteen BALB/c mice were randomly divided into three groups: RSV pneumonia model group(M), QFOL-treated group(Q) and the control group(C). Serum proteomes were analyzed and compared using a label-free quantitative LC-MS/MS approach. A total of 172 protein groups, 1009 proteins, and 1073 unique peptides were successfully identified. 51 differentially expressed proteins(DEPs) were identified(15 DEPs when M/C and 43 DEPs when Q/M; 7 DEPs in common). Classification and interaction network showed that these proteins participated in various biological processes including immune response, blood coagulation, complement activation, and so forth. Particularly, fibrinopeptide B(FpB) and heparin cofactor Ⅱ(HCII) were evaluated as important nodes in the interaction network, which was closely involved in coagulation and inflammation. Further, the Fp B level was increased in Group M but decreased in Group Q, while the HCII level exhibited the opposite trend. These findings not only indicated FpB and HCII as potential biomarkers and targets of QFOL in the treatment of RSV pneumonia, but also suggested a regulatory role of QFOL in the RSV-induced disturbance of coagulation and inflammation-coagulation interactions.展开更多
OBJECTIVE:To evaluate the add-on effect of Qinbei Qingfei Yiqi(QBQFYQ) granules for ventilator-associated pneumonia(VAP) in non-infectious critically ill patients.METHODS:In this randomized controlled trial, 80non-inf...OBJECTIVE:To evaluate the add-on effect of Qinbei Qingfei Yiqi(QBQFYQ) granules for ventilator-associated pneumonia(VAP) in non-infectious critically ill patients.METHODS:In this randomized controlled trial, 80non-infectious critically ill patients undergoing mechanical ventilation in the intensive care unit(ICU)were randomly divided into two groups:those receiving QBQFYQ granules plus usual treatment(experimental group, n = 50) and those receiving only the usual treatment(control group, n = 30).The main outcome measures were VAP rate, time of VAP occurrence, duration of mechanical ventilation,and length of ICU stay.Interleukin-6(IL-6), C-reactive protein(CRP), and T-lymphocyte(CD4+, CD8+,and CD4+/CD8+ ratio) serum levels were also evaluated before and after treatment.RESULTS:Compared with the control group treatment, QBQFYQ administration significantly reduced the duration of mechanical ventilation [(9.58± 3.14) vs(12.52 ± 4.33) days] and length of ICU stay [(14.57 ± 3.72) vs(17.82 ± 5.24) days] and delayed VAP occurrence [(4.31 ± 0.86) vs(2.43 ± 0.27)days].Additionally, CRP and IL-6 serum levels and CD4+/CD8+ ratio were significantly lower in the experimental group(P < 0.05) than in the control group.However, there were no significant differences in hospital mortality rate(30.0% vs 33.3%) and adverse events(4.0% vs 6.7%).CONCLUSION:QBQFYQ delays the time of VAP occurrence and shortens the duration of mechanical ventilation in non-infectious critically ill patients,possibly through anti-inflammatory and immunomodulatory mechanisms.展开更多
OBJECTIVE:To study the anti-inflammatory and anti-tussive effects of Qingfei Dayuan granules(清肺达原颗粒,QFDY),and to evaluate the acute and sub-chronic toxicity of QFDY.METHODS:Anti-inflammatory effects were evaluat...OBJECTIVE:To study the anti-inflammatory and anti-tussive effects of Qingfei Dayuan granules(清肺达原颗粒,QFDY),and to evaluate the acute and sub-chronic toxicity of QFDY.METHODS:Anti-inflammatory effects were evaluated by murine model of xylene induced ear edema in mice.Ear swelling degree was calculated and tumor necrosis factor-α,interleukin-1βand interleukin-6 were determined.Anti-tussive evaluations were carried out in the mouse cough model induced by ammonia liquor.Latent period cough and number of cough within 3 min were counted.In acute toxicity study,the rats were randomly divided into test group and solvent control group.Body weighs,food intakes and general clinical signs were monitored.In the sub-chronic toxicity study,QFDY was administered to rats at 0,4,8 and 16 g/kg per day for 28 and 30 d of post treatment was conducted.Mortalities,clinical signs,body weight changes,food intakes,ophthalmological examinations,hematological parameters,biochemical indicators,electrolyte indicators,urinalyses and histopathological examinations were monitored.RESULTS:QFDY significantly inhibited the development of ear edema in anti-inflammatory assay and decreased cough frequency caused by ammonia liquor.The results presented a dose-effect relationship.In acute toxicity study,no abnormality exhibited at dose of 24.0 g/kg per day during the 14-d observation period.In the sub-chronic toxicity study,higher reticulocyte count,lymphocyte and lower Cl-,blood urea nitrogen were analyzed compared with the solvent control group.But the differences were considered to be incidental and not clinically toxic.Obvious dose-effect relationship of urine color was observed,and the three test groups at the end of the experiments resulted in significant increase in urobilinogen,bilirubin,ketone body and urine leukocyte.However,all the positive indicators returned to normal in the recovery period.Therefore,no toxicological changes were found during the study period.CONCLUSION:QFDY showed significant anti-inflammatory and anti-tussive effects in mice.The lethal dose(LD50)of per oral QFDY in rats was estimated to be more than 24.0 g/kg per day and the no observed adverse effect level was over 16 g/kg per day,which suggested that QFDY is relatively safe for oral medication at the present dose on rats.Our experimental results provide a reference for the further development and research of QFDY.展开更多
Objective To investigate the efficacy of Qingfei Yihuo Capsules(清肺抑火胶囊,QYCs)in preventing the air pollution associated exacerbation of chronic obstructive pulmonary disease(COPD).Methods This was a prospective,p...Objective To investigate the efficacy of Qingfei Yihuo Capsules(清肺抑火胶囊,QYCs)in preventing the air pollution associated exacerbation of chronic obstructive pulmonary disease(COPD).Methods This was a prospective,parallel,single-blind,randomized,placebo-controlled trial.Sixty patients with stable Group D COPD were randomly allocated to receive either oral QYCs(intervention group)or placebos(control group,30 cases per group)for 15 days in the presumed high-incidence air pollution season and followed-up for 1 year.Both groups were given individualized Western medicine therapy according to the Global Initiative for Chronic Obstructive Lung Disease criteria as usual.Total and separate numbers of acute exacerbation(AE)associated with striking air pollution was the primary outcomes.Secondary outcomes included total numbers of deteriorating respiratory symptoms and separate numbers associated with striking air pollution,as well as scores of COPD Assessment Test(CAT)and modified Medical Research Council Scale(mMRC).Results All the 60 patients completed the study.There was no statistical significance in total numbers of AE between the two groups(P>0.05).Compared with the control group,a significant reduction in air-pollution associated numbers of deteriorated respiratory symptoms was observed in the intervention group(1.9–1.2 vs.3.6–2.4,P<0.01).At the end of follow-up,there was no significant difference in CAT and mMRC scores between the two groups(P>0.05).Only 2 patients in the intervention group reported diarrhea and recovered after drug discontinuance.Conclusion For patients with Group D COPD,oral QYCs in high-incidence season of air pollution can effectively mitigate respiratory symptoms associated with air pollution,although there was no evidence that it had a significant reductive effect on AEs.(Registered at Chinese Clinical Trial Registry,registration No.ChiCTR-IOR-17013827).展开更多
基金Supported by the Science and Medicine Joint Fund Project of Natural Science Foundation of Hunan Province(2022JJ80001).
文摘[Objectives]To investigate the clinical effect of Yinhuang Qingfei capsules in the treatment of asymptomatic and mild/common severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection.[Methods]A total of 362 patients with SARS-CoV-2 infection were divided into the treatment group with 242 patients and control group with 120 patients according to their treatment regimen.The patients in the control group were given standard treatment regimen and those in the treatment group were given Yinhuang Qingfei capsules in addition to the treatment in the control group.The two groups were observed in terms of average length of hospital stay,mean time for nucleic acid clearance,TCM syndrome score,and progression to severe/critical illness,and clinical outcome was compared between the two groups.[Results]There was a significant difference in the overall response rate between the treatment group and the control group[97.52%(236/242)vs 95.00%(114/120),P<0.05].Compared with the control group,the treatment group had significantly shorter length of hospital stay and time for nucleic acid clearance(P<0.05).After 7 days of treatment,both groups had a significant change in TCM syndrome score,and there was a significant difference in TCM syndrome score between the two groups(P<0.05);after 15 days of treatment,both groups had a TCM syndrome score of 0.Progression to severe/critical illness was not observed in either group.[Conclusions]Compared with the standard treatment regimen alone,standard treatment regimen combined with Yinhuang Qingfei capsules can effectively shorten the length of hospital stay and time for nucleic acid clearance and improve TCM symptoms in patients with asymptomatic and mild/common SARS-CoV-2 infection.
文摘This work is aimed to study the therapeutics and pharmacology of the treatment of severe acute respiratory infection caused by coronavirus disease-19 (COVID-19) with traditional Chinese medicine (TCM) “Qingfei Paidu Decoction”. We analyze the “Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia” (Version I to Version VII) made by China, “Clinical management of severe acute respiratory infection when novel coronavirus <span style="font-family:Verdana;">(2019-nCoV) infection is suspected—Interim guidance” made by World Healt</span><span style="font-family:Verdana;">h Organization (WHO), “Therapeutic Guidelines: Respiratory” published by Australia, and the origin of classical prescription of Qingfei Paidu Decoction: “Shanghan Lun (Treatise on Febrile Diseases)” and “Jinkui Yaolue (Synopsis of Golden Chamber)”. We search the dictionary of traditional Chinese medicine (Version II) manually. We search literatures from 2001 to 2020 on Wiley online library. We conduct a comparative study on the therapeutic options and indications among Qingfei Paidu Decoction, COVID-19 and chronic obstructive pulmonary disease (COPD). And we carry out pharmacological inquiry of Qingfei Paidu Decoction. The therapeutic options and indications of Qingfei Paidu Decoction in China, COVID-19 and COPD are considered to be basically consistent. Qingfei Paidu Decoction has a definite therapeutic effect on the symptoms, basic diseases and complications for COVID-19 and COPD. Qingfei Paidu Decoction is a possible choice of </span><span style="font-family:Verdana;">phytotherapy </span><span style="font-family:Verdana;">for severe acute respiratory infection caused by COVID-19.</span>
基金This work was supported by Natural Science Foundation of China(81674020).
文摘Objective:Qingfei oral liquid(QF),an experimental Chinese medicine prescription developed from the ancient priscription of traditional Chinese medicines Ma Xin Shi Gan decoction and Tingli Dazao Xie Fei decoction,has been effectively used since decades to treat patients with viral pneumonia and asthma.In our previous study,we had demonstrated that QF can significantly reduce airway hyperresponsiveness,hyperemia,lung tissue edema,inflammatory lung tissue infiltration in mice,airway mucus secretion,and peripheral airway collagen hyperplasia;however,its mechanism of action is unknown.Methods:Fifty 6–8-week-old male BALB/c mice were equally and randomly divided into five groups:the control,ovalbumin(OVA),OVA+respiratory syncytial virus(RSV),QF,and dexamethasone(Dxms)groups.The QF group was administered QF at 1.17 g·kg−1·d−1,the Dxms group received dexamethasone injections at 0.2 mg·kg−1·d−1,and the remaining groups were administered PBS.Inflammation in the lung tissue was assessed by hematoxylin and eosin(HE),periodic acid–Schiff(PAS),and Van Gieson staining.ELISA was used to evaluate the IL-13,IL-25,and IL-33 in the mice.Western blotting was used to examine changes in the proteins levels of transient receptor potential vanilloid-1(TRPV1)and mucin 5AC(MUC5AC)in the lung tissues of mice.Results:Histopathological evaluation revealed that the OVA and OVA+RSV groups exhibited lung tissue edema and inflammatory lung tissue infiltration in the HE staining and airway secretions in the PAS staining;collagen hyperplasia around the airway was increased in these two groups compared with the control group.The QF group exhibited significantly reduced lung tissue edema,inflammatory lung tissue infiltration,airway secretions,and collagen hyperplasia around the airway compared with the OVA+RSV group.We analyzed the serum levels of IL-13,IL-25,and IL-33 in the mice and found that these levels were higher in the OVA and OVA+RSV groups than in the control group(P<0.05 in the OVA group,P<0.01 in the OVA+RSV group).The QF group exhibited significantly decreased serum levels of IL-13,IL-25,and IL-33 compared with the OVA+RSV group(all P<0.05).The Dxms group also exhibited significant decreases in the serum levels of IL-13 and IL-33(all P<0.05)but no significant decrease in the serum levels of IL-25 compared with the RSV+OVA group.Finally,we examined the protein levels of TRPV1 and MUC5AC in the lung tissues of mice using Western blotting.After identifying RSV infection in the mice with asthma,the protein levels of TRPV1 and MUC5AC in the lung tissues of mice were significantly higher than those in the control group(P<0.05,P<0.01).We found that compared with RSV+OVA,QF can significantly downregulate the protein level of TRPV1;further,the protein level of MUC5AC was also significantly reduced(all P<0.001).Conclusion:QF can inhibit RSV replication and reduce airway inflammation and mucus hypersecretion injury caused by RSV infection and asthma,and its mechanism of action may be associated with the downregulation of TRPV1 expression and a decrease in airway mucus hypersecretion injury.
基金The emergency project for COVID-19 prevention and control of Beijing university of Chinese medicine (2020-JYB-YJ-006)
文摘Objective:To explore the possible mechanism of Qingfei Paibu Decoction in the treatment of COVID-19 from the perspective of cytokine storm by network pharmacology.Methods: The TCMSP and SymMap databases were used to screen out the active components and targets of Qingfei Paibu Decoction;The GeneCards database was used to screen the predicted targets of COVID-19;Two targets were mapped;The STRING database and Cytoscape3.7.2 software were used to construct the network diagram of active drag-ingredient-target and screen out the core components and targets;The GO enrichment analysis and KEGG pathway enrichment analysis were carried out by OmicShare cloud platform and David respectively.Results:A total of 52 potential targets of Qingfei Paibu Decoction for the treatment of COVID-19 were obtained, among which 17 were core targets related to inflammation, mainly including cytokines such as IL, IFN, TNF and chemokines. And 26 core components were obtained, including quercetin, luteolin, kaempferol, naringenin, and baicalein;The GO enrichment results showed 224 biological processes, 15 molecular functions and 33 cell components related to inflammation;There were 5 inflammatory signaling pathways in KEGG enrichment results, including TNF signaling pathway, Nod-like receptor signaling pathway, Toll-like receptor signaling pathway, MAPK signaling pathway and cytokine receptor interaction. Conclusion: Qingfei Paibu Decoction can inhibit cytokine storms by acting on multiple targets and pathways with multiple components and thus treat COVID-19.
基金National Natural Science Foundation of China(No.81473592)Changchun University of Traditional Chinese Medicine graduate student“JuJing Cup”academic research and innovation project(No.FK201922).
文摘The coronavirus disease 2019(COVID-19)was a newly discovered infectious respiratory disease and characterized by wide prevalence,high incidence rate and fast progress and dangerous,which belonged to the category of"cold-wet plague"in TCM.The onset of COVID-19 was caused by pestilence,which mingled with seasonal cold-dampness and invaded the human body when external defensive qi was weak and then leaded to the accumulation of Yang qi.Different from exogenous pathogenic factors transmitted from the external to the internal or followed the transmission law of Wei,Qi,Ying and Xue,the nature of pestilence belonged to the category of pathogenic fire,spreading as soon as possible,from the external to the internal and from the upper and lower part of triple energizer,even to every part.At the very beginning,the pestilence attacked from the Taiyang meridian into the Yangming meridian quickly,or straight into the three Yang meridian,which was called"triple-yang combination of diseases".Manifestations of fever,aversion to cold and pain of body were conformed to the exterior syndrome of Taiyang,as well as manifestations of fullness and discomfort in chest,vomiting and spitting and diarrhea were conformed to the syndrome of half-interior-half-exterior;And symptoms manifested as high fever,faint,and abdominal fullness and constipation were conformed to the syndrome of Yangming;But sometimes,there was cold-dampness surrounding the exterior at the beginning along with intense interior pathogenic fire.Or at the beginning,the exterior factors invaded into three Yin meridians quickly while have not been eliminated,which may lead to the syndrome of inner blocking causing collapse or Jue exhaustion.The most typical syndrome of COVID-19 was triple-yang combination of diseases,which was often seen in mild,moderate and part of severe cases.Hence"Qingfei Paidu Decoction"was prescribed especially for this kind of syndrome.Its accurate efficacy has been proved by that mild cases converting to severe cases in the mobile cabin hospital have been effectively restrained and thus the progression of the disease has blocked.Composition analysis showed that Mahuang decoction with Maxing Shigan decoction was to relieve exterior Taiyang syndrome,Xiaochaihu decoction was for harmonizing half-superficies and half-interior Shaoyang syndrome,and large dose of gypsum was used to clear interior heat of the Yangming meridian,and Shegan Mahuang decoction and Xiaoqinglong plus gypsum decoction was for lowering the adverse qi and resolving fluid,and Wuling San was for warming the triple energizer and transforming qi and draining water."Qingfei Paidu Decoction"was an syncretic innovation of classical prescriptions from Treatise on Febrile Diseases,which was not made up of herbs but multiple concordant prescriptions helping to get twice the result with half the effort,so that the"cold-wet plague"can be quickly discharged.
基金Research Project of Guangdong Provincial Bureau of Traditional Chinese Medicine(No.20222183,20221320)Guangzhou Traditional Chinese Medicine and Integrated Traditional Chinese and Western Medicine Technology Project(No.20222A010020)。
文摘Objective:To investigate the mechanism of regulation of airway neurogenic inflammation by Qiaoqin Qingfei agent in rats with cough variant asthma(CVA).Methods:48 SD rats were randomly divided into blank group,model group,montelukast sodium group(1.05 mg/kg)and high,medium and low dose groups(26,13,6.5 g/kg),with 8 rats in each group.The rat CVA model was established by the method of ovalbumin(OVA)combined with aluminum hydroxide(Al(OH)3)sensitization and repeated stimulation.From the second day of sensitization,the rat CVA model was given by gavage for 28 days.The pathological changes of lung tissue were observed under microscope by HE staining.The content changes of nerve growth factor(NGF)and substance P(SP)in alveolar lavage fluid(BALF)were determined by double-antibody sandwich ABC-ELISA,and the protein expression levels of NGF and SP in lung tissue were detected by immunohistochemistry.Results:Pathological findings showed significant inflammatory manifestations in the model group,and the inflammatory infiltration in the high-dose,medium-dose and low-dose groups of Qiaoqin Qingfei agent and montelukast sodium groups were alleviated to varying degrees.Compared with blank group,the protein expression levels of NGF and SP in lung tissue of model group were significantly increased(P<0.01).Compared with model group,the protein expression levels of NGF and SP in lung tissue and the contents of NGF and SP in alveolar lavage fluid in high-dose,medium-dose and low-dose groups and montelukast sodium group were significantly decreased(P<0.05).Conclusion:Qiaoqin Qingfei agent may reduce airway inflammation and relieve cough variant asthma by regulating the protein expression levels of NGF and SP in airway neurogenic inflammation.
文摘Objective： To observe the effect of traditional Chinese medicine （TCM） Qingfei powder on the radiotherapy-related pneumonia in patient with non-small-cell lung cancer （NSCLC） and explore its underlying mechanism. Methods： 120 NSCLC patients with the diagnosis of both radiotherapy-related pneumonia and deficiency of Qi and Yin were randomly divided into the treatment group and the model group. The patients in treatment group were given Qingfei power plus regular treatment and those in the model group were given the regular treatment. The period of observation is 30 days. Results： The combination of effective and markedly effective ratio in patients treated with Qingfei power was much higher than that in patients with regular treatment （70% vs 51.7%, P=0.04）. Conclusion： Qingfei power could nourish Qi and Yin as well as clear away lung-heat and dispel phlegm, leading to the relief of clinical symptom in NSCLC patients with radiotherapy-related pneumonia. It demonstrates that the deficiency of both Qi and Yin maybe the main Zheng pattern of patients with radiotherapy-related pneumonia.
文摘Objective: To explore the effects of Qingfei Xiaoyan pill combined with ceftriaxone and azithromycin on immune index, oxidative stress and inflammatory index in senile CAP patients. Methods: A total of 130 patients with CAP admitted to Yulin first hospital from October 2016 to December 2017 were randomly divided into control group (n = 65) and observation group (n = 65), the control group was treated with ceftriaxone combined with azithromycin, while the observation group was treated with Qingfei Xiaoyan Pill on the basis of the control group, the changes of cellular humoral immune function, oxidative stress index and inflammatory factors were compared between the two groups before and after treatment. Results: After treatment, the levels of CD4+ and CD4+/CD8+ in both groups were significantly higher than before treatment, while the level of CD8+ was significantly lower than before treatment, the levels of CD4+ and CD4+/CD8+ in the observation group were significantly higher than those in the control group, while the level of CD8+ was significantly lower than those in the control group;the levels of IgA and IgM in the observation group were significantly higher than those in the control group;the levels of MDA and SOD in the observation group were significantly lower than those in the control group, and the level of MDA in the observation group was significantly lower than that in the control group, the levels of SOD in the observation group were significantly higher than those in the control group;the levels of PCT and CRP in the two groups were significantly lower than those before treatment , and the levels of PCT and CRP in the observation group were significantly lower than those in the control group. Conclusions:Qingfei Xiaoyan pill combined with ceftriaxone and azithromycin can effectively enhance the immune function of elderly patients with CAP, enhance the body's antioxidant effect and reduce its inflammatory reaction, which is of clinical significance.
基金Supported by Key project of National Key R&D Program of China in 2022(2022YFC2502700).
文摘[Objectives]This study was conducted to explore the curative effect of Qingfei Ditan decoction combined with targeted drug penetration therapy of traditional Chinese medicine on severe mycoplasma pneumonia in children.[Methods]Based on the retrospective study method,children with severe mycoplasma pneumonia admitted to the Children s Hospital of Soochow University from April 2023 to October 2023 were selected,and divided into a treatment group including 56 cases and a control group including 145 cases.The curative effect and adverse reactions of the two groups were compared.[Results]The total effective rate of the treatment group was higher than that of the control group,and the disappearance time of cough and lung rales was shorter than that of the control group,and the incidence of adverse reactions was lower,showing statistical significance(P<0.05).However,defervescence time and bronchoscope flushing rate showed no significant difference(P>0.05).[Conclusions]Qingfei Ditan Decoction combined with targeted drug penetration therapy of traditional Chinese medicine has a significant effect on severe mycoplasma pneumonia in children,and can reduce the side effects of drugs.It is a safe and efficient combination treatment scheme of traditional Chinese medicine.
基金Beijing Traditional Chinese Medicine Foundation for Science and Technology(JJ-2020-78):Research on the Protection of Intellectual Property Rights of Traditional Chinese MedicineScientific and Technological Innovation Project of China Academy of Chinese Medical Sciences(CI2021A00912):Basic and Translational Research on the Application of Traditional Chinese Medicine+1 种基金the Research Foundation of Major New Drug Creation,from the Ministry of Science and Technology of China(2018ZX09721003-009-022):Research on Key Technologies and Industrialization of Traditional Chinese Medicine Preparations for ChildrenNational Natural Science Foundation of China(82074060):Study on the Effect of Tanyu Tongzhi Fang in Maintaining Vascular Homeostasis in the Treatment of Atherosclerosis。
文摘OBJECTIVE:To explore how Qingfei Zhisou oral liquid(清肺止嗽口服液,QFZS)adjusts body temperature bias and the interaction of inflammatory factors levels and metabolomic differences.METHODS:Dry yeast was subcutaneously injected at 10 mL/kg to establish the pyrexia model.We randomly divided 60 Sprague-Dawley rats into five groups:control,model,positive,low dose of QFZS and high dose of QFZS.Inflammatory proteins were evaluated by Western blotting and immunohistochemistry.For the examination of the endogenous metabolites,enzyme linked immunosorbent assay and ultra-high-performance liquid chromatography high-resolution mass spectrometry were employed.RESULTS:QFZS significantly reduced rats'body temperature within 6 h after dry yeast injection and reduced the secretion of the arginine vasopressin,cyclic adenosine monophosphate,prostaglandin E-2,tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),and interleukin-1βin serum.Meanwhile,we identified 41 metabolites between the model and QFZS groups,including arachidonic acid and lysophospholipids.QFZS restored normal arachidonic acid levels.Based on the differential metabolite enrichment analysis,QFZS's antiinflammatory and anti-pyrexia effects might be related to the inflammatory pathway regulated by transient receptor potential.Additionally,QFZS treatment reduced transient receptor potential melastatin 2 ion channel expression and affected TNF-α,heat shock protein 70,and cyclooxygenase-2 expression in the hypothalamus.CONCLUSION:QFZS exerts its regulatory effects on fever by regulating the metabolism of lysophospholipids and arachidonic acid and the regulation of inflammation via transient receptor potential ion channels channels.
基金supported by the National Natural Science Foundation of China (No. 81973906)。
文摘Objective: Qingfei Tongluo Plaster(QFP), an improved Chinese medicine hospital preparation, is an attractive treatment option due to its well clinical efficacy, convenience, economy, and patient compliance in the treatment of respiratory syncytial virus(RSV) pneumonia. The aim of this study was to investigate the efficacy mechanism of QFP on RSV rats from the perspective of alleviating lung inflammation and further explore the changes of serum metabolites and metabolic pathways in RSV rats under the influence of QFP.Methods: This study used network pharmacological methods and molecular docking combined with molecular biology and metabolomics from multi-dimensional perspectives to screen and verify the therapeutic targets. Open online databases were used to speculate the gene targets of efficient ingredients and diseases. Then, we used the String database to examine the fundamental interaction of common targets of drugs and diseases. An online enrichment analysis was performed to predict the functional pathways. Molecular docking was applied to discover the binding modes between essential ingredients and crucial gene targets. Finally, we demonstrated the anti-inflammatory ability of QFP in the RSV-evoked pneumonia rat model and explained the mechanism in combination with the metabolomics results.Results: There were 19 critical targets defined as the core targets: tumor necrosis factor(TNF), inducible nitric oxide synthase 2(NOS2), mitogen-activated protein kinase 14(MAPK14), g1/S-specific cyclin-D1(CCND1), signal transducer and activator of transcription 1-alpha/beta(STAT1), proto-oncogene tyrosine-protein kinase Src(SRC), cellular tumor antigen p53(TP53), interleukin-6(IL6), hypoxiainducible factor 1-alpha(HIF1A), RAC-alpha serine/threonine-protein kinase(AKT1), signal transducer and activator of transcription 3(STAT3), heat shock protein HSP 90-alpha(HSP90AA1), tyrosine-protein kinase JAK2(JAK2), cyclin-dependent kinase inhibitor 1(CDKN1A), mitogen-activated protein kinase 3(MAPK3), epidermal growth factor receptor(EGFR), myc proto-oncogene protein(MYC), protein c-Fos(FOS) and transcription factor p65(RELA). QFP treated RSV pneumonia mainly through the phosphatidylinositol 3-kinase(PI3K)/RAC AKT pathway, HIF-1 pathway, IL-17 pathway, TNF pathway, and MAPK pathway. Animal experiments proved that QFP could effectively ameliorate RSV-induced pulmonary inflammation. A total of 28 metabolites underwent significant changes in the QFP treatment, and there are four metabolic pathways consistent with the KEGG pathway analyzed by network pharmacology,suggesting that they may be critical processes related to treatment.Conclusion: These results provide essential perspicacity into the mechanisms of action of QFP as a promising anti-RSV drug.
基金supported by Research on the Modernisation of Traditional Chinese Medicine in National Key R&D Programmes(No.2018YFC1704804 and 2018YFC1704800)the Sixth Special Support Program for Innovative Leading Talents in Anhui(No.T000614).
文摘Background Chronic obstructive pulmonary disease(COPD),a common respiratory disease,can be effectively treated by traditional Chinese medicine(TCM).Qingfei Huatan,a TCM formula,has been reported to effectively alleviate the clinical symptoms of COPD patients.However,there is a lack of multi-centre,randomised,double-blind,controlled clinical trials documenting the clinical efficacy and safety of this formula in the treatment of acute exacerbation of COPD(AECOPD).Objective This study evaluated the efficacy and safety of Qingfei Huatan formula in the treatment of AECOPD,thereby providing high-quality clinical evidence.Design,setting,participants and interventions A total of 276 patients with AECOPD were included in this multi-centre,randomised,double-blind,placebo-controlled trial and were randomised into treatment and control groups at a ratio of 1:1.Patients in the treatment and control groups took Qingfei Huatan granules or simulated Qingfei Huatan granules twice a day,for 14 days,in addition to Western medicine treatment.All patients were followed up for 3 months.Main outcome measures The primary outcome was time taken to symptom stabilisation.The secondary outcomes included duration of antibiotic use,clinical symptom and sign score,TCM syndrome score,dyspnoea score,and quality of life(QOL)score.Meanwhile,the safety of the formula was assessed through routine urine and stool tests,electrocardiograms,liver and kidney function tests,and the observation of adverse events throughout the trial.Results The time taken for effective stabilisation(P<0.05)and obvious stabilisation(P<0.01),and the duration of antibiotic use(P<0.05)were significantly shorter in the treatment group than in the control group.On days 6,9,12 and 14 of treatment,clinical symptom and sign score decreased in both groups,particularly in the treatment group(P<0.01).On days 9,12 and 14 of treatment,the TCM syndrome scores of both groups were reduced(P<0.01),with more significant reductions in the treatment group.At 3 months after the end of treatment,the treatment group continued to have lower clinical symptom and sign score and TCM syndrome score than the control group(P<0.01).On days 6,9,12 and 14 of treatment,dyspnoea and QOL scores were markedly reduced in the two groups(P<0.05 and P<0.01,respectively),especially in the treatment group.At 3 months after the end of treatment,dyspnoea and QOL scores were lower in the treatment group than those in the control group(P<0.01).No serious adverse events were observed in either group.Conclusion The Qingfei Huatan formula can effectively shorten the duration of AECOPD and antibiotic use,significantly relieve clinical symptoms,and increase QOL for AECOPD patients,with a favourable safety profile.These results suggest that this formula can be used as a complementary treatment for AECOPD patients.
文摘目的探究凉血清肺汤联合硝黄搽剂湿敷治疗面部脂溢性皮炎肺胃热盛证的临床效果。方法回顾性选取2022年1月—2023年1月期间收治的面部脂溢性皮炎肺胃热盛证患者102例,根据随机数字表法分为研究组(51例),常规组(51例)。常规组进行硝黄搽剂湿敷治疗,研究组采用凉血清肺汤联合硝黄搽剂湿敷治疗。比较治疗结束后患者临床疗效,比较治疗结束后患者湿疹面积及严重程度指数(eczema area severity index,EASI)、整体评分(investigator′s global assessment,IGA)、基质金属蛋白酶-3(matrix metalloproteinase-3,MMP-3)、白细胞介素-1β(interleukin-1β,IL-1β)水平,并比较治疗期间的不良反应情况。结果治疗后,两组患者中医症状评分较治疗前均降低(P<0.05),且研究组低于常规组(P<0.05),研究组、常规组治疗总有效率分别为94.12%(48/51)、72.55%(37/51),研究组较常规组高(P<0.05),治疗后两组IGA、EASI评分降低,研究组较常规组低(P<0.05),两组面部脂溢性皮炎肺胃热盛证患者治疗后MMP-3、IL-1β水平降低,研究组MMP-3、IL-1β水平较常规组低(P<0.05),两组患者不良反应率比较,差异均无统计学意义(P>0.05)。结论凉血清肺汤联合硝黄搽剂湿敷能够提高面部脂溢性皮炎肺胃热盛证患者的临床疗效,缓解症状,降低IGA、EASI评分,改善血清炎症水平,安全性较高。
基金Supported by Beijing Municipal Science and Technology Commission(No.Z151100003815020)the Capital Fund for the Development of Medical Science(TCM Board.No.SF-2007-Ⅲ-23)the Traditional Chinese Medicine Science and Technology Development Fund Project of Beijing(No.JJ2012-09)
文摘Objective： To explore the effect and mechanism of Qingfei Mixture （清肺合剂）, a Chinese medicine, in treating mycoplasma pneumonia （MP） in MP patients and rat model. Methods： A total of 46 MP children with phlegm heat obstructing Fei （Lung） syndrome were randomly assigned to two groups by the method of random number table, with 23 children in each group. The control group was treated with intravenous infusion of azithromycin; the treatment group received intravenous infusion of azithromycin and oral administration of Qingfei Mixture. The treatment course was 7 days. Major symptoms and minor symptoms were observed and scored before and after treatments. A rat model of MP was also established. A total of 120 wistar rats were randomly divided into 5 groups： a normal group, infection group, Qingfei Mixture treatment group, azithromycin treatment group, and Qingfei Mixture ＋ azithromycin treatment group. Each group contained 24 rats, from which every 6 were euthanatized 1, 3, 7 and 14 days after infection. MP DNA in pulmonary tissue homogenates was detected using real-time fluorescence quantitative polymerase chain reaction. Pathology was assessed after hematoxylin （HE） staining and lung tissue pathology scores were determined in pulmonary tissue. Transmission electron microscopic detection and electronic image analysis were performed on lung tissue 3 days after infection. Intedeukin （IL）-17 was detected in serum using enzymelinked immunosorbent assay （ELISA） 7 days after infection. Results： In the clinical study, both control and the treatment group showed improved results on removing symptoms of phlegm heat syndrome compared to the control group （P〈0.05）. In animal experiments, On the 7th day after MP infection, as detected by electron microscopy, the pulmonary capillary basement membranes of the azithromycin ＋ Qingfei Mixture treatment group were much thinner than those of the azithromycin or Qingfei mixture treatment groups （P〈0.05）. The level of serum IL-17 in the azithromycin ＋ Qingfei Mixture treatment group was lower than that in the azithromycin or Qingfei Mixture groups （P〈0.01）. Conclusion： Both Qingfei Mixture and azithromycin have therapeutic effects on mycoplasma pneumoniae pneumonia, but the combination of both agents had the greatest effect.
基金supported by the National Natural Science Foundation of China(No.81574025)the Open Project Program of Jiangsu Key Laboratory of Pediatric Respiratory Disease,Nanjing University of Chinese Medicine(No.JKLPRD201410)
文摘Respiratory syncytial virus(RSV) is a leading cause of acute lower respiratory tract infections. Qingfei oral liquid(QFOL), a traditional Chinese medicine, is widely used in clinical treatment for RSV-induced pneumonia. The present study was designed to reveal the potential targets and mechanism of action for QFOL by exploring its influence on the host cellular network following RSV infection. We investigated the serum proteomic changes and potential biomarkers in an RSV-infected mouse pneumonia model treated with QFOL. Eighteen BALB/c mice were randomly divided into three groups: RSV pneumonia model group(M), QFOL-treated group(Q) and the control group(C). Serum proteomes were analyzed and compared using a label-free quantitative LC-MS/MS approach. A total of 172 protein groups, 1009 proteins, and 1073 unique peptides were successfully identified. 51 differentially expressed proteins(DEPs) were identified(15 DEPs when M/C and 43 DEPs when Q/M; 7 DEPs in common). Classification and interaction network showed that these proteins participated in various biological processes including immune response, blood coagulation, complement activation, and so forth. Particularly, fibrinopeptide B(FpB) and heparin cofactor Ⅱ(HCII) were evaluated as important nodes in the interaction network, which was closely involved in coagulation and inflammation. Further, the Fp B level was increased in Group M but decreased in Group Q, while the HCII level exhibited the opposite trend. These findings not only indicated FpB and HCII as potential biomarkers and targets of QFOL in the treatment of RSV pneumonia, but also suggested a regulatory role of QFOL in the RSV-induced disturbance of coagulation and inflammation-coagulation interactions.
基金Supported by the Natural Science Foundation of Heilongjiang Province-Intervention of Qinbei Qingfei Yiqi granules' preparation on ventilator-associated pneumonia(No.D201125)
文摘OBJECTIVE:To evaluate the add-on effect of Qinbei Qingfei Yiqi(QBQFYQ) granules for ventilator-associated pneumonia(VAP) in non-infectious critically ill patients.METHODS:In this randomized controlled trial, 80non-infectious critically ill patients undergoing mechanical ventilation in the intensive care unit(ICU)were randomly divided into two groups:those receiving QBQFYQ granules plus usual treatment(experimental group, n = 50) and those receiving only the usual treatment(control group, n = 30).The main outcome measures were VAP rate, time of VAP occurrence, duration of mechanical ventilation,and length of ICU stay.Interleukin-6(IL-6), C-reactive protein(CRP), and T-lymphocyte(CD4+, CD8+,and CD4+/CD8+ ratio) serum levels were also evaluated before and after treatment.RESULTS:Compared with the control group treatment, QBQFYQ administration significantly reduced the duration of mechanical ventilation [(9.58± 3.14) vs(12.52 ± 4.33) days] and length of ICU stay [(14.57 ± 3.72) vs(17.82 ± 5.24) days] and delayed VAP occurrence [(4.31 ± 0.86) vs(2.43 ± 0.27)days].Additionally, CRP and IL-6 serum levels and CD4+/CD8+ ratio were significantly lower in the experimental group(P < 0.05) than in the control group.However, there were no significant differences in hospital mortality rate(30.0% vs 33.3%) and adverse events(4.0% vs 6.7%).CONCLUSION:QBQFYQ delays the time of VAP occurrence and shortens the duration of mechanical ventilation in non-infectious critically ill patients,possibly through anti-inflammatory and immunomodulatory mechanisms.
基金Department of Science and Technology of Hubei Province:Preclinical Study on Qingfei Dayuan granules (No.2021BGE017)
文摘OBJECTIVE:To study the anti-inflammatory and anti-tussive effects of Qingfei Dayuan granules(清肺达原颗粒,QFDY),and to evaluate the acute and sub-chronic toxicity of QFDY.METHODS:Anti-inflammatory effects were evaluated by murine model of xylene induced ear edema in mice.Ear swelling degree was calculated and tumor necrosis factor-α,interleukin-1βand interleukin-6 were determined.Anti-tussive evaluations were carried out in the mouse cough model induced by ammonia liquor.Latent period cough and number of cough within 3 min were counted.In acute toxicity study,the rats were randomly divided into test group and solvent control group.Body weighs,food intakes and general clinical signs were monitored.In the sub-chronic toxicity study,QFDY was administered to rats at 0,4,8 and 16 g/kg per day for 28 and 30 d of post treatment was conducted.Mortalities,clinical signs,body weight changes,food intakes,ophthalmological examinations,hematological parameters,biochemical indicators,electrolyte indicators,urinalyses and histopathological examinations were monitored.RESULTS:QFDY significantly inhibited the development of ear edema in anti-inflammatory assay and decreased cough frequency caused by ammonia liquor.The results presented a dose-effect relationship.In acute toxicity study,no abnormality exhibited at dose of 24.0 g/kg per day during the 14-d observation period.In the sub-chronic toxicity study,higher reticulocyte count,lymphocyte and lower Cl-,blood urea nitrogen were analyzed compared with the solvent control group.But the differences were considered to be incidental and not clinically toxic.Obvious dose-effect relationship of urine color was observed,and the three test groups at the end of the experiments resulted in significant increase in urobilinogen,bilirubin,ketone body and urine leukocyte.However,all the positive indicators returned to normal in the recovery period.Therefore,no toxicological changes were found during the study period.CONCLUSION:QFDY showed significant anti-inflammatory and anti-tussive effects in mice.The lethal dose(LD50)of per oral QFDY in rats was estimated to be more than 24.0 g/kg per day and the no observed adverse effect level was over 16 g/kg per day,which suggested that QFDY is relatively safe for oral medication at the present dose on rats.Our experimental results provide a reference for the further development and research of QFDY.
基金Supported by the National Key Research and Development Program of China(No.2018YFC1313600)Medical Guide Project of Shan ghai Science and Tech no logy Commissi on(No.14401970700)+1 种基金Traditional Chinese Medicine Research Grant from Committee on Health and Family Planning in Shanghai(No.2014LP004A)and the Industry-University-Research-Medicine Modern Chinese Medicine Project of Shanghai Science and Technology Commission(No.15DZ1900202)。
文摘Objective To investigate the efficacy of Qingfei Yihuo Capsules(清肺抑火胶囊,QYCs)in preventing the air pollution associated exacerbation of chronic obstructive pulmonary disease(COPD).Methods This was a prospective,parallel,single-blind,randomized,placebo-controlled trial.Sixty patients with stable Group D COPD were randomly allocated to receive either oral QYCs(intervention group)or placebos(control group,30 cases per group)for 15 days in the presumed high-incidence air pollution season and followed-up for 1 year.Both groups were given individualized Western medicine therapy according to the Global Initiative for Chronic Obstructive Lung Disease criteria as usual.Total and separate numbers of acute exacerbation(AE)associated with striking air pollution was the primary outcomes.Secondary outcomes included total numbers of deteriorating respiratory symptoms and separate numbers associated with striking air pollution,as well as scores of COPD Assessment Test(CAT)and modified Medical Research Council Scale(mMRC).Results All the 60 patients completed the study.There was no statistical significance in total numbers of AE between the two groups(P>0.05).Compared with the control group,a significant reduction in air-pollution associated numbers of deteriorated respiratory symptoms was observed in the intervention group(1.9–1.2 vs.3.6–2.4,P<0.01).At the end of follow-up,there was no significant difference in CAT and mMRC scores between the two groups(P>0.05).Only 2 patients in the intervention group reported diarrhea and recovered after drug discontinuance.Conclusion For patients with Group D COPD,oral QYCs in high-incidence season of air pollution can effectively mitigate respiratory symptoms associated with air pollution,although there was no evidence that it had a significant reductive effect on AEs.(Registered at Chinese Clinical Trial Registry,registration No.ChiCTR-IOR-17013827).
